uniQure completes $345 million public offering to fund gene therapy pipeline

LEXINGTON, Mass. and AMSTERDAM - Gene therapy company uniQure N.V. (NASDAQ:QURE), whose stock has surged over 200% year-to-date according to InvestingPro data, has closed its previously announced public offering, raising approximately $345 million in gross proceeds, according to a press release statement issued Monday.

The offering consisted of 6,736,841 ordinary shares sold at $47.50 per share, including 947,368 additional shares issued after underwriters fully exercised their option. The company also issued pre-funded warrants to purchase 526,316 ordinary shares to certain investors at the same price less the $0.0001 exercise price per warrant.

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen served as bookrunning managers for the offering, with H.C. Wainwright & Co. acting as lead manager.

uniQure plans to use the net proceeds to fund commercialization readiness activities, the potential commercial launch of AMT-130, development of other clinical product candidates, business development initiatives, and general corporate purposes.

The offering was made under uniQure’s automatically effective shelf registration statement filed with the SEC on January 7, 2025.

uniQure focuses on developing gene therapies for patients with severe medical needs. The company has previously received approval for a hemophilia B gene therapy and is advancing a pipeline that includes treatments for Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease.

In other recent news, uniQure N.V. announced the pricing of its public offering, aiming to raise approximately $300 million. The company priced 5,789,473 ordinary shares at $47.50 each and offered pre-funded warrants for an additional 526,316 shares at the same price, minus a nominal exercise fee. The transaction is expected to close around September 29, 2025, pending customary conditions. In analyst updates, Guggenheim significantly raised its price target for uniQure to $95 from $28, maintaining a Buy rating. This adjustment follows favorable data from uniQure’s AMT-130 treatment for Huntington’s disease. Cantor Fitzgerald also increased its price target to $80 from $47, maintaining an Overweight rating. The firm updated its probability-of-success estimates for AMT-130, reflecting increased confidence in both U.S. and EU5 markets. These developments highlight recent shifts in analyst perspectives and financial strategies for uniQure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.